Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 9/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947328 | 0.89 | MET (0.45) | METHTR6KDM2B | |
| SCHEMBL3220703 | 0.87 | HTR6 (0.44) | HTR6HTR2CKDM2B | |
| SCHEMBL3223782 | 0.87 | HTR6 (0.47) | METHTR6HTR1AKDM2B | |
| SCHEMBL3214560 | 0.86 | HTR6 (0.50) | METHTR6 | |
| SCHEMBL3216915 | 0.85 | KDM2B (0.41) | HTR6HTR1AKDM2B | |
| SCHEMBL3218158 | 0.84 | HTR6 (0.45) | HTR6HTR2CKDM2B | |
| SCHEMBL3214442 | 0.84 | HTR6 (0.46) | METHTR6HTR1A | |
| SCHEMBL3215703 | 0.84 | HTR6 (0.54) | METHTR6 | |
| SCHEMBL3207359 | 0.83 | NPC1 (0.42) | HTR6HTR2CNPC1TDP1 | |
| SCHEMBL3218478 | 0.81 | POLB (0.46) | HTR6KDM2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | claimed |
| WO-2010021797-A1 | CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010021797-A1 | CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021797-A1 | CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | MET 914/4885HTR6 1/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.